Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk shares tumble 11% after company forecasts sales declines this year
12:06pm, Tuesday, 03'rd Feb 2026
Novo Nordisk said late Tuesday it sees sales and profit growth declining this year, expecting a U.S. sales hit. Novo's American depositary shares fell 11% on the news.
Novo Nordisk Posts Better-Than-Expected 2025 Sales. Stock Sinks.
12:04pm, Tuesday, 03'rd Feb 2026
The Ozempic and Wegovy maker reports full-year sales of 309.1 billion Danish krone, beating analysts' forecasts.
Novo Nordisk warns of 2026 sales decline
11:59am, Tuesday, 03'rd Feb 2026
Wegovy maker Novo Nordisk expects a decline in sales this year, it said on Tuesday as it reported fourth-quarter operating profit slightly above forecasts.
NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study
11:46am, Tuesday, 03'rd Feb 2026
Novo Nordisk reports that CagriSema beats semaglutide at HbA1c reduction and weight loss in a 68-week phase III diabetes study, with no weight-loss plateau.
Novo Nordisk releases 2026 sales and operating profit outlook
11:37am, Tuesday, 03'rd Feb 2026
In 2025, Novo Nordisk's sales increased by 10% and operating profit increased by 6%, compared to previously issued guidance of 8 to 11% sales growth and
Citi flags bigger tests ahead after Novo Nordisk diabetes trial success
08:48am, Tuesday, 03'rd Feb 2026
Bank says latest CagriSema results meet expectations, with investor focus shifting to head-to-head data against Eli Lilly's tirzepatide. Novo Nordisk (NYSE:NVO) has reported positive headline results
Citi flags bigger tests ahead after Novo Nordisk diabetes trial success
08:31am, Tuesday, 03'rd Feb 2026
Bank says latest CagriSema results meet expectations, with investor focus shifting to head-to-head data against Eli Lilly’s tirzepatide. Novo Nordisk...
Novo Nordisk warns of 2026 sales decline, shares fall
08:27am, Tuesday, 03'rd Feb 2026
Novo Nordisk (NYSE:NVO) shares fell almost 13% on Tuesday as the Danish drugmaker forecast lower sales and profit growth for 2026, citing reduced prices in...
Independent Advisor Alliance Sells 22,441 Shares of Novo Nordisk A/S $NVO
04:54am, Tuesday, 03'rd Feb 2026
Independent Advisor Alliance trimmed its position in shares of Novo Nordisk A/S (NYSE: NVO) by 37.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Excha
M2i Global announces first gallium shipment from Nimy Resources’ Mons project in Western Australia to United States
04:05am, Tuesday, 03'rd Feb 2026
M2i Global Inc (OTC:MTWO) and Volato Group announced on Tuesday that Nimy Resources has initiated its first shipment of high-grade gallium ore from Western...
NextSource signs LOI with Japan’s Hanwa, JOGMEC for potential UAE anode plant investment
03:58am, Tuesday, 03'rd Feb 2026
NextSource Materials Inc. (TSX:NEXT, OTCQB:NSRCF) said it has signed a non-binding letter of intent with Japan’s Hanwa Co Ltd and the Japan Organization for...
Nextech3D.ai signs Tier 1 enterprise deal, expands Krafty Lab to international in-person events
03:40am, Tuesday, 03'rd Feb 2026
Nextech3D.AI (CSE:NTAR, OTCQX:NEXCF, FRA:1SS) announced that its Krafty Lab platform has expanded to support international in-person enterprise event...
Nichols & Pratt Advisers LLP MA Grows Position in Novo Nordisk A/S $NVO
03:22am, Tuesday, 03'rd Feb 2026
Nichols and Pratt Advisers LLP MA lifted its stake in shares of Novo Nordisk A/S (NYSE: NVO) by 1.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 500,991 shar
Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge
12:29am, Tuesday, 03'rd Feb 2026
Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling the GLP‑1
Novo Nordisk's Next-Gen Combination Drug Beats Semaglutide in Weight Loss and Blood Sugar Control
02:12pm, Monday, 02'nd Feb 2026
Novo Nordisk reported new Phase 3 trial results showing CagriSema led to greater weight loss and HbA1c reduction than semaglutide in people with type 2 diabetes.
